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Abstract
Background: Erythropoietin-producing hepatocellular receptor A2 (EPHA2) is overexpressed on the cell surface in many
cancers and predicts poor prognosis. DS-8895a is a humanized anti-EPHA2 IgG1 monoclonal antibody afucosylated to
enhance antibody-dependent cellular cytotoxicity activity. We conducted a two-step, phase I, multicenter, open-label
study to determine the safety, tolerability, and pharmacokinetics of DS-8895a in patients with advanced solid tumors.
Methods: Step 1 was a dose escalation cohort in advanced solid tumor patients (six dose levels, 0.1–20mg/kg) to
determine Step 2 dosing. Step 2 was a dose expansion cohort in EPHA2-positive esophageal and gastric cancer patients.
DS-8895a was intravenously administered every 2 weeks for the duration of the study, with a 28-day period to assess
dose-limiting toxicity (DLT). Safety, pharmacokinetics, tumor response, and potential biomarkers were evaluated.
Results: Thirty-seven patients (Step 1: 22, Step 2: 15 [9: gastric cancer, 6: esophageal cancer]) were enrolled. Although one
DLT (Grade 4 platelet count decreased) was observed in Step 1 (dose level 6, 20mg/kg), the maximum tolerated dose was
not reached; the highest dose (20mg/kg) was used in Step 2. Of the 37 patients, 24 (64.9%) experienced drug-related
adverse events (AEs) including three (8.1%) with Grade ≥ 3 AEs. Infusion-related reactions occurred in 19 patients (51.4%) but
were manageable. All patients discontinued the study (evident disease progression, 33; AEs, 4). Maximum and trough serum
DS-8895a concentrations increased dose-dependently. One gastric cancer patient achieved partial response and 13 patients
achieved stable disease. Serum inflammatory cytokines transiently increased at completion of and 4 h after the start of DS-
8895a administration. The proportion of CD16-positive natural killer (NK) cells (CD3−CD56+CD16+) decreased 4 h after the
start of DS-8895a administration, and the ratio of CD3−CD56+CD137+ to CD3−CD56+CD16+ cells increased on day 3.
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Conclusions: Twenty mg/kg DS-8895a infused intravenously every 2weeks was generally safe and well tolerated in patients
(n= 21) with advanced solid tumors. The exposure of DS-8895a seemed to increase dose-dependently and induce activated
NK cells.
Trial registration: Phase 1 Study of DS-8895a in patients with advanced solid tumors (NCT02004717; 7 November 2013 to 2
February 2017); retrospectively registered on 9 December 2013.
Keywords: Erythropoietin-producing hepatocellular receptor A2, Gastric cancer, Esophageal cancer, Advanced solid tumors,
DS-8895a, Antibody-dependent cellular cytotoxicity, Phase I study
Background
Erythropoietin-producing hepatocellular receptor A2
(EPHA2) is a 130 kDa type-I transmembrane tyrosine kinase
receptor, and EPH-related receptor tyrosine kinase ligand A1
(EPHRIN-A1) is the principle ligand for EPHA2 [1].
EPHA2/EPHRIN-A1 signaling contributes to the mainten-
ance of epithelial cell homeostasis [1–3]. EPHA2 is expressed
in several normal human tissues including skin, colon, blad-
der, kidney, lung, and stomach [4–6]. EPHA2 is overex-
pressed in many types of cancers [7–13], including 60% of
gastric cancers [5] and nearly 50% of esophageal cancers
[14]. It is widely reported that EPHA2 overexpression is cor-
related with poor prognosis for cancer patients [1, 4, 15–17].
Overexpressed EPHA2 promotes tumor cell proliferation,
migration, invasion, and metastasis; and EPHA2 is activated
through phosphorylation at serine-897 by AKT, p90 riboso-
mal S6 kinases, and protein kinase A, but not by EPHRIN-
A1 [1–3, 18, 19]. In addition, Ras-Erk signaling, which is
frequently activated in aggressive tumors, promotes expres-
sion of EPHA2 [20]. These features of EPHA2 make it an at-
tractive target for cancer therapy.
Fragment crystallizable gamma receptor IIIa (FcγRIIIa,
CD16) is highly expressed on natural killer (NK) cells.
FcγRIIIa/CD16 binds to the Fc portion of IgG antibodies
and induces the release of perforin and granzyme upon
antibody/target cell binding, resulting in the death of target
cells. This process is called antibody-dependent cellular
cytotoxicity (ADCC). Afucosylation of the carbohydrate
chain in IgG1 Fc substantially potentiates the binding affin-
ity of the IgG1 portion to FcγRIIIa/CD16, which results in
enhancement of ADCC [21, 22]. DS-8895a is a humanized
anti-EPHA2 IgG1 monoclonal antibody (Additional file 1)
that is afucosylated to enhance ADCC (POTELLIGENT®;
BioWa Inc., Princeton, NJ, USA) and is expected to pro-
duce antitumor effects on EPHA2-overexpressing tumor
cells through ADCC, as demonstrated in pre-clinical stud-
ies [23]. DS-8895a had neither complement-dependent
cytotoxicity nor agonist activity against EPHA2 in vitro,
and only weakly inhibited EPHRIN-A1-mediated phosphor-
ylation of EPHA2 [23]. ADCC function is associated with
antigen density [24], and overexpression of EPHA2 in solid
tumors is considered a suitable and promising target for
the ADCC-enhanced antibody DS-8895a.
The promising findings in pre-clinical studies led us to the
clinical development of DS-8895a. We aimed to assess the
safety, tolerability, and pharmacokinetics (PK) of DS-8895a
administered in repeat doses to patients with advanced solid
tumors and EPHA2-positive gastric or esophageal cancer in
this first-in-human study of DS-8895a. Additionally, tumor
response and potential biomarkers of tumor response were
explored.
Methods
Study objectives
The primary objectives of this phase I, multicenter, open-
label study, were to assess the safety, tolerability, and PK
of repeated dosing of DS-8895a in patients with advanced
solid tumours and to determine its optimal dose for sub-
sequent clinical studies. The secondary objectives were to
explore tumor response to DS-8895a treatment and the
potential biomarkers related to DS-8895a.
Patients
Inclusion criteria were as follows: advanced solid tumors in
Step 1, immunohistologically confirmed EPHA2-positive
gastric or esophageal cancer in Step 2, refractory to stand-
ard treatment or no standard treatment available, age ≥ 20
years old, Eastern Cooperative Oncology Group perform-
ance status ≤1, sufficient organ function within 7 days prior
to registration (Additional file 2), adverse drug reaction of
prior anti-cancer therapy resolved to Grade 1 or Grade 2
and assessed as clinically eligible by investigators, certain
treatment-free period from the final dose/treatment of any
previous therapy to the date of registration (Add-
itional file 3), life expectancy ≥3months, and written in-
formed consent to the study including agreement to
biomarker analysis of archival and biopsied tumor samples.
A tumor was considered EPHA2-positive if ≥25% of tumor
cells had weak to moderate (score 2+) or strong (3+)
EPHA2 staining immunohistochemically.
Major exclusion criteria were as follows: symptomatic
or treatment-required brain metastasis within 6months of
registration; positive for hepatitis B surface antigen, hepa-
titis C virus, or human immunodeficiency virus antibody;
active gastrointestinal hemorrhage requiring blood trans-
fusions within 2 weeks of registration; treatment with
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other investigational drugs within 3 weeks of registration;
lactating or pregnant mothers; and unwillingness to use
adequate contraception during the study and for 6months
after the final DS-8895a administration.
Study design and treatment
The study protocol, amendments, and informed consent
forms were approved by the Institutional Review Boards at
each study site, and the study was conducted in accordance
with the ethical principles of the Declaration of Helsinki
and the International Council for Harmonisation guideline
for Good Clinical Practice, and followed all other applicable
regulatory requirements in Japan. Research using samples
for genome/gene analysis was conducted in compliance
with the Ethical Guidelines for Human Genome/Gene Ana-
lysis Research [25] and the Ethical Guideline for Clinical
Research [26] as well as the above guidelines. This study
was registered at clincaltrials.gov (NCT02004717).
This phase I study conducted in Japan comprised two
steps: Step 1 as the dose escalation cohort in patients
with advanced solid tumors, and Step 2 as the dose ex-
pansion cohort in patients with EPHA2-positive esopha-
geal and gastric cancers (Additional file 4). In Step 1, the
dose of DS-8895a was sequentially increased from Level
1 (0.1 mg/kg) to Level 6 (20 mg/kg), and intravenously
administered over 2 h every 2 weeks with a 28-day
period for assessment of dose-limiting toxicity (DLT).
Each dose level consisted of three or six patients. If no
DLT was observed in the first three patients, the dose
level was escalated. If a DLT occurred in 1/3 patients,
three patients were added to that dose level. If 2/6 or 3/
6 patients experienced a DLT, dose escalation was dis-
continued and the dose level was judged as maximum
tolerated dose (MTD). If the first 2/3 or 3/3 patients ex-
perienced a DLT, this dose level was also judged as
MTD. In this case, further evaluation of the previous
dose level was conducted, adding three or more patients.
If the initial dose level was MTD, the study was stopped.
Intra-patient dose escalation was not allowed. DLTs are
defined in Additional file 5. Infusion-related reactions
(IRRs) were excluded from the DLT evaluation.
The starting dose and administration schedule of DS-
8895a were determined based on data from unpublished
studies of intravenous administration of DS-8895a to cyno-
molgus monkeys (data on file, Daiichi Sankyo Co., Ltd.).
Starting dose of 0.1mg/kg was 260 times lower than the
calculated human equivalent dose of no-observed-adverse-
effect level obtained in these studies. An administration
schedule of 2 weeks was chosen based on PK in cynomol-
gus monkeys and mice after a single intravenous or intra-
peritoneal administration of DS-8895a, respectively.
In Step 2, safety and PK were evaluated in up to 20 pa-
tients at the dose determined in Step 1. In both Steps 1
and 2, one cycle consisted of 4 weeks, and multiple
cycles were allowed unless the discontinuation criteria
for an individual patient were met.
Discontinuation criteria included evident disease pro-
gression, an adverse event (AE) making treatment con-
tinuation difficult, postponement of the study treatment
> 4 weeks, deviation from the inclusion criteria after
registration, patient’s request of withdrawal from study
treatment, and investigator’s judgement.
Administration of DS-8895a was postponed if the patients
did not meet the following criteria: ≥1000/μL neutrophil
count, ≥75000/μL platelet count, non-hematological toxicity
≤ Grade 2 or improvement to the baseline level. Cancer
treatment other than DS-8895a was prohibited from the day
of obtaining informed consent to the day of follow-up assess-
ment (30–45 days after final administration). Treatment for
concomitant symptoms of cancer was allowed.
Safety and tolerability assessments
All AEs, clinical laboratory tests (hematology, blood
chemistry, and urinalysis), vital signs (systolic and dia-
stolic blood pressure, pulse rate, body temperature), and
electrocardiogram (ECG) were assessed according to the
National Cancer Institute – Common Terminology Cri-
teria for Adverse Events, version 4.0 (Japanese version).
Initially, no premedication was used to prevent IRRs.
However, after IRRs were observed at dose Levels 1 and
2, the protocol was amended to allow a premedication
with antihistamines and antipyretics in Level 3, and a
premedication with additional corticosteroids in Level 4
and thereafter. If no IRR occurred in previous DS-8895a
administration, it could be omitted from subsequent
doses.
Pharmacokinetic assessments
In Cycles 1 and 2, blood samples for PK analysis were col-
lected immediately before and after DS-8895a administra-
tion; 4, 7, 24, and 72 h after starting administration on day
1; any time point on day 8; immediately before and after
the next DS-8895a administration on day 15; and immedi-
ately before subsequent DS-8895a administration on day
29. From Cycle 3, blood samples were taken immediately
before and after DS-8895a administration on day 1. Blood
was also collected on the day of study discontinuation and
on the 30th day after the final dose.
The serum concentrations of DS-8895a in Cycles 1
and 2 were used to calculate PK parameters (maximum
serum concentration [Cmax], time to reach maximum
serum concentration [Tmax], area under the concentra-
tion-time curve [AUClast] up to the last quantifiable
time, AUC during dosing interval, AUC up to infinity
[AUCinf], and terminal elimination half-life [T1/2]) using
non-compartment models and the WinNonlin® software
program (Certara, Princeton, USA). The lower limit of
detection was set at 1000 ng/mL.
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Pharmacodynamics assessments
Archival tumor samples were assessed for EPHA2, E-cad-
herin, human epidermal growth factor receptor 2 (HER2),
and epidermal growth factor receptor (EGFR) expression
(Steps 1 and 2). In Step 2, tumor biopsy samples were ob-
tained before Cycle 1 and 2, and EPHA2, CD16, NKp46/
NCRI, CD3, CD68, programmed death ligand-1 (PD-L1),
E-cadherin, EGFR, and HER2 expression were assessed by
immunohistochemistry. EPHA2 was detected using anti-
human EPHA2 mouse monoclonal antibodies (clones 018
and 058, Daiichi Sankyo Co., Ltd.).
Blood and serum samples were collected to test circu-
lating CD16-positive NK cells, NK activity, human
leukocyte antigen (HLA)/killer cell immunoglobin-like
receptor (KIR) mismatch, cytokines, and soluble EPHA2;
a detailed blood sampling schedule is given in Add-
itional file 6. HLA/KIR mismatch was assessed by typing
these genes using previously described methods [27].
Circulating CD16-positive NK cells (CD3−CD56+CD16+,
in Steps 1 and 2) and the ratio of CD3−CD56+ CD137+
cells to CD3−CD56+CD16+ cells (only in Step 2) in blood
samples were analyzed using flow cytometry. Circulating
soluble EPHA2 (only in Step 2) in serum was analyzed
by sandwich ELISA. Cytokines (granulocyte-macrophage
colony-stimulating factor, interferon [IFN]γ, interleukin
[IL]-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-18,
macrophage inflammatory protein [MIP]-1α, MIP-1β,
monocyte chemotactic protein [MCP]-1, tumor necrosis
factor [TNF]α, and TNFβ) in serum samples were ana-
lyzed by multiplex assays (in Steps 1 and 2). Natural
cytotoxicity (NK cell activity) of NK cells was assessed
by measuring the ability of the patient’s peripheral blood
mononuclear cells to lyse K562 cells in vitro before
Cycle 1 in Step 2.
Efficacy assessments
Tumor response to DS-8895a (best overall response, dur-
ation of best overall response, response rate, and disease
control rate) was evaluated using the Response Evaluation
Criteria in Solid Tumors, Version 1.1., using transverse
section images of computerized tomography or magnetic
resonance imaging scans. All baseline evaluations were
performed using images taken within 21 days of registra-
tion. Tumor evaluation was performed every 6 weeks (± 1
week), or whenever investigators considered necessary.
Statistical analysis
The Guidelines for the Clinical Evaluation of Anti-can-
cer Drugs [28] were used to determine the sample size
for Step 1. For Step 2, the sample size of up to 20 pa-
tients was estimated to be sufficient to evaluate safety
and efficacy of DS-8895a.
Summary statistics were calculated for all categorical and
quantitative data. The Kaplan–Meier method was used to
estimate the survival distribution function for time-to-event
analyses. Progression-free survival (PFS) was defined as the
time from the first dose of DS-8895a to progression, re-
lapse, or death from any cause, whichever occurred first.
Pre-planned analytical populations consisted of an efficacy
analysis set (patients who received at least one dose of the
study drug and had at least one tumor assessment), an
MTD evaluable set (patients who received at least one dose
of the study drug in Step 1), a PK and pharmacodynamics
analysis set (patients who received at least one dose of the
study drug and from whom appropriate samples were ob-
tained), and a safety analysis set (patients who received at
least one dose of the study drug). SAS® System Release 9.2
software (SAS Institute Inc., Cary, NC) was used to perform
statistical analysis.
Results
Patients
In total, 37 patients (22 in Step 1 and 15 in Step 2) were en-
rolled from 7 November 2013 to 2 February 2017. The num-
ber of patients (total [Step 1, Step 2]) in each pre-planned
analysis set was as follows: safety analysis set (37 [22, 15]), ef-
ficacy analysis set (36 [21, 15]), MTD evaluable analysis set
(21, [21, 0]), PK analysis set (36 [21, 15]), and pharmaco-
dynamics analysis set (37 [21, 15]). One patient in Step 1
(Level 6) was excluded from the efficacy, PK, and MTD ana-
lysis sets because of unavailable efficacy/PK data or unevalu-
able DLT due to an IRR, which prevented the patient from
completing the initial DS-8895a administration/finishing the
trial.
Patient characteristics are shown in Table 1 and were
similar between patients in Steps 1 and 2. Overall, 76%
of patients were male with an average age of 67 years.
EPHA2 expression was positive (2+ and 3+) in approxi-
mately one-third of patients tested in Step 1. In Step 2,
72 patients were screened and 27 were positive for
EPHA2 expression; 15 of these 27 patients met the eligi-
bility criteria and were included in Step 2. All 37 en-
rolled patients received the study treatment and
eventually discontinued the study. Most patients discon-
tinued because of evident disease progression (20 in Step
1 and 13 in Step 2), and all others discontinued because
of adverse events (Additional file 7).
Safety
In Step 1, only one DLT was observed in one patient at
Level 6 (20 mg/kg) as Grade 4 platelet count decreased.
This was the only drug-related serious AE (SAE) and the
only AE that required a dose delay in this study. MTD
was not reached within the pre-planned doses. The dose
for Step 2 was determined to be the highest dose from
Step 1: 20 mg/kg.
AEs of any grade were observed in 21 (95.5%) and 15
(100%) patients in Steps 1 and 2, respectively (Table 2). The
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most common AEs were chills, decreased appetite, pyrexia,
hypotension, nausea, anemia, hypoxia, constipation, dry
skin, cancer pain, and vomiting. Drug-related AEs were ob-
served in 14 patients (63.6%) in Step 1 and 10 patients
(66.7%) in Step 2. The frequency of Grade 3 or 4 AEs was
less than 10% in both Steps. IRRs related to DS-8895a oc-
curred in 13 patients (59.1%) in Step 1 and 6 (40.0%) in
Step 2. Among these patients, transient interruption of DS-
8895a infusion was required in 10 patients. One patient in
Level 3 (1.0mg/kg) discontinued treatment because of a
Grade 3 IRR, syncope. All other IRRs were Grade 1 or 2.
In Steps 1 and 2, there were nine AEs in four patients
that led to discontinuation of study treatment. Of these,
AEs of hypoesthesia, hypotension, peripheral coldness,
nausea, and vomiting occurred in a single patient on the
day of the first dose and immediately resolved after ces-
sation of DS-8895a infusion. These five events were de-
termined as being related to DS-8895a while the
remaining four AEs were symptoms associated with dis-
ease progression. Therefore, a single patient of the 37
patients enrolled in the study (2.7%) discontinued treat-
ment due to DS-8895a-related toxicity. Eleven SAEs oc-
curred in seven patients including three deaths due to
disease progression, and all were unrelated to DS-8895a
except for the Grade 4 platelet decreased previously
mentioned.
No clinically relevant differences from baseline or consist-
ent trends were observed for other laboratory parameters
(blood chemistry, hematology, and urology), vital signs, and
ECG.
Pharmacokinetics
The mean maximum and trough serum concentrations
of DS-8895a increased as the dose increased. PK param-
eters (Cmax and AUC) increased with increasing dose of
DS-8895a (Table 3) for both Cycles 1 and 2. No
Table 1 Patient characteristics
Step 1 Step 2
(n = 22) (n = 15)
Sex, Male 15 (68) 13 (87)
Age, year (mean [range]) 68 (56–78) 66 (49–76)
Weight, kg (mean [range]) 55 (40–85) 55 (42–70)
Height, cm (mean [range]) 162 (148–178) 165 (160–173)
Cancer typea
Gastric 16 (73) 9 (60)
Esophageal 4 (18) 6 (40)
Colorectal 1 (5) 0 (0)
NSCLC 2 (9) 0 (0)
Thyroid 1 (5) 0 (0)
Primary tumor
Present 11 (50) 8 (53)
Prior cancer therapy
Chemotherapy 22 (100) 15 (100)
No. of regimens (mean [range]) 4.4 (2–7) 4.5 (2–8)
Surgery 10 (46) 8 (53)
Radiation 3 (14) 4 (27)
EPHA2 expressionb
0 10 (46) 0 (0)
1+ 2 (9) 0 (0)
2+ 6 (27) 13 (87)
3+ 1 (5) 2 (13)
N (%) unless otherwise stated
Abbreviations: NSCLC, non–small-cell lung cancer; EPHA2, erythropoietin-
producing hepatocellular receptor A2
aPatients with more than one type of cancer were repeatedly counted
bData were presented only for patients who have been examined for
EPHA2 expression
Table 2 Adverse events (AEs)
Step 1 Step 2
(n = 22) (n = 15)
AEs, any grades 21 (95.5) 15 (100)
AEs, grade≥ 3 5 (22.7) 8 (53.3)
Drug-related AEs, any grades 14 (63.6) 10 (66.7)
Drug-related AEs, grade≥ 3 2 (9.1) 1 (6.7)
Syncope 1 (4.5) 0 (0.0)
Anemia 1 (4.5) 0 (0.0)
White blood cell count decreased 1 (4.5) 0 (0.0)
Lymphocyte count decreased 0 (0.0) 1 (6.7)
Neutrophil count decreased 1 (4.5) 0 (0.0)
Platelet count decreaseda 1 (4.5) 0 (0.0)
Infusion-related reactionb,c 13 (59.1) 6 (40.0)
Chills 9 (40.9) 3 (20.0)
Grade 1 5 (22.7) 3 (20.0)
Grade 2 4 (18.2) 0 (0.0)
Pyrexia 5 (22.7) 4 (26.7)
Grade 1 4 (18.2) 4 (26.7)
Grade 2 1 (4.5) 0 (0.0)
Hypotension 5 (22.7) 2 (13.3)
Grade 1 2 (9.1) 2 (13.3)
Grade 2 3 (13.6) 0 (0.0)
Hypoxia 4 (18.2) 1 (6.7)
Grade 1 1 (4.5) 0 (0.0)
Grade 2 3 (13.6) 1 (6.7)
Nausea 4 (18.2) 0 (0.0)
Grade 1 3 (13.6) 0 (0.0)
Grade 2 1 (4.5) 0 (0.0)
N (%)
aGrade 4 platelet count decreased was judged as a dose-limiting toxicity
bMajor reactions that occurred in four or more patients were presented
cNo Grade 3 or 4 infusion-related adverse events occurred
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apparent trends were observed for Tmax. The mean T1/2
of DS-8895a was 10–14 days in patients treated with 1.0
mg/kg or higher.
Efficacy
One gastric cancer patient in Step 2 achieved partial re-
sponse (PR) (6.7%). Stable disease (SD) was observed in
seven patients (33.3%; 95% confidence interval [CI]: 14.6,
57.0) of Step 1 and six patients (40.0%; 95% CI: 16.3,
67.7) of Step 2 (Table 4). Tumor shrinkage demonstrated
no clear correlation with DS-8895a dose (Fig. 1) or
EPHA2 expression (Table 4).
The median (range) duration of study treatment was
4.1 (0.14–31) weeks for 22 patients in Step 1 and 5.1
(2.1–22) weeks for 15 patients in Step 2. Time to re-
sponse of the PR patient was 5.1 weeks, and duration of
response was 18.4 weeks. In the patients with PR and
SD, the median (range) duration of disease control was
11.7 (5.0–34) weeks. The median (range) PFS for Steps 1
and 2 were 5.9 (4.0–34.3) and 6.0 (3.3–23.4) weeks,
respectively.
Pharmacodynamics
Serum levels of IFN-γ, IL-6, IL-7, IL-8, IL-10, MIP-1α,
MIP-1β, MCP 1, and TNFα increased transiently at
completion of DS-8895a administration and 4 h after the
start of administration in Cycle 1. Elevated serum levels
returned to baseline at 24 h. Soluble EPHA2 protein
levels increased over time from baseline levels to day 8
of Cycle 2 in Step 2. Various levels of NK cell activity
were observed in all patients before the first dose of DS-
8895a in Step 2. Levels of circulating CD16-positive NK
cells in the blood decreased 4 h after start of DS-8895a
administration and remained low at 24 h in Cycle 1 of
Step 1 (Fig. 2a) and Step 2 (Fig. 2b). The ratio of
CD3−CD56+CD137+ cells to CD3−CD56+CD16+ cells in-
creased on day 3 of Cycle 1 in Step 2, compared with
baseline (Fig. 2c). There were no apparent relationships
between the levels or changes of these biomarkers and
tumor responses.
Mismatch of HLA/KIR polymorphism was detected in
20 patients (2 matched) in Step 1 and 14 patients (1
matched) in Step 2. All three patients with matched
HLA/KIR had progressive disease. No association with
tumor response could be determined because of the high
incidence of HLA/KIR mismatch.
EPHA2, E-cadherin, HER2, and EGFR expression in
retained tumor tissues; and EPHA2, CD16, NKp46/
NCRI, CD3, CD68, PD-L1, E-cadherin, EGFR, and HER2
expression in paired biopsies obtained before Cycle 1
and 2 also demonstrated no apparent relationship be-
tween these expression levels or changes in expression
levels and tumor responses. Pre- and post-treatment
tumor tissues from the patient who achieved PR showed
high expression of PD-L1 and E-cadherin at baseline,
which decreased after DS-8895a administration. Also, in
this patient, the number of infiltrated CD3-positive cells
increased after DS-8895a treatment.
Discussion
Here we report the results of the first-in-human study of
DS-8895a, an afucosylated, humanized anti-EPHA2 anti-
body. DS-8895a was safe and well tolerated up to 20mg/
kg in patients with advanced solid tumors (Step 1) and
EPHA2-positive gastric or esophageal cancer (Step 2).
Although one DLT event was observed at 20 mg/kg in
Step 1, the MTD was not reached. The safety of a 20
mg/kg dose level was further confirmed in Step 2. IRRs
were reported in about half of the patients but were gen-
erally manageable. One patient with EPHA2-positive
gastric cancer achieved PR and 13 patients showed SD
as best response. Serum DS-8895a concentrations and
exposure increased in a dose-dependent manner, as ex-
pected. The mean T1/2 of DS-8895a was 10–14 days in
patients treated with 1.0 mg/kg or higher and a stable
concentration level was reached after long-term treat-
ment, suggesting that administration every 2 weeks is a
reasonable treatment schedule.
In this study, a decrease in CD16-positive NK cells
and a transient increase in serum inflammatory cyto-
kines were observed after DS-8895a administration, both
of which indicate DS-8895a ADCC activity. Reduction of
CD16-positive NK cells was maintained for 24 h, which
was consistent with reports of other ADCC-enhanced
antibodies [29, 30], suggesting a decrease in CD16-posi-
tive NK cells by ADCC. The increase in cytokines might
also contribute to the occurrence of IRRs, which has
been reported for other types of afucosylated monoclo-
nal antibodies [31, 32].
We also observed that the ratio of
CD3−CD56+CD137+ cells to CD3−CD56+CD16+ cells in-
creased from baseline to Day 3 of Cycle 1. It has been
reported that induction of ADCC activity upregulates
CD137 expression on NK cells [33, 34], and increased
CD137 expression on circulating NK cells has also been
identified in patients treated with cetuximab, an anti-
EGFR antibody with ADCC activity [35]. However, no
apparent relationship was noted between this ratio and
the best overall response in this study, given that we had
only one patient who achieved PR. This suggests that
enhanced ADCC activity by our afucosylated antibody
was not sufficient to induce strong tumor shrinkage in
solid tumors. The addition of an agonistic anti-CD137
monoclonal antibody with other antibodies, such as
cetuximab or anti-CD20 antibody, has shown that acti-
vation of CD137 on NK cells enhanced their antitumor
activity [34, 35]. A previous study suggested that the
combination of HLA and KIR gene polymorphisms may
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affect ADCC activity [36]. However, as HLA/KIR mis-
match was present in most patients in both Step 1 and
Step 2, we were unable to assess a relationship between
HLA/KIR mismatch and ADCC activity in our study.
Additional investigations of pharmacodynamic bio-
markers conducted in Step 2 — including NK cell activ-
ity before the first study treatment and tumor expression
levels of EPHA2, CD16, NKp46/NCRI, CD3, CD68, PD-
L1, E-cadherin, EGFR, and HER2 — yielded no apparent
trends of correlation between baseline level or on-treat-
ment changes of these biomarkers and best overall re-
sponse or disease control ratio. In Step 2, patients with
EPHA2-positive gastric or esophageal cancer were en-
rolled. However, only one patient achieved a response,
indicating that patient enrichment or drug activity may
not have been sufficient. The patient who achieved PR
had higher PD-L1 expression at baseline compared with
the other patients and showed an increase in CD3-posi-
tive cells in Cycle 2 and decreased PD-L1 expression
compared with baseline levels. Activated NK cells can
stimulate the activity of other immune processes
through their release of cytokines (such as IFNγ), pro-
viding a link to initiate subsequent immune responses to
attack target tumors, which may have resulted in a
tumor response in this patient. Preclinical studies using
combination treatment of DS-8895a with other agents
such as immune check point inhibitors are warranted.
As the first-in-human study of DS-8895a, this study
has provided initial insights into the safety and poten-
tial activity of DS-8895a in patients and their re-
sponse to the drug, providing a valuable knowledge
base for future studies of afucosylated, humanized
antibodies for the treatment of solid tumors. While
clinical recommendations cannot be made based on
this early-stage study, our phase I clinical study results
warrant further studies involving a greater number of pa-
tients to determine the significance of our reported obser-
vations in relation to the treatment of EPHA2-positive
solid tumors. Exploratory pharmacodynamic analysis sug-
gested that immunological change was induced by our
afucosylated monoclonal antibody with enhanced ADCC
activity, which warrants further investigations to assess
the efficacy of DS-8895a with different combinations of
immune checkpoint inhibitors.
Limitations
One limitation of this study was that only Japanese pa-
tients were involved; therefore, the generalizability of the
findings to other ethnic populations may be limited.
Additionally, the PFS results from this single-arm study
(without comparators) are considered exploratory.
Conclusions
This study showed that 20 mg/kg DS-8895a adminis-
tered by infusion every 2 weeks was generally safe and
well tolerated in patients with advanced solid tumors
and that serum concentrations of DS-8895a increased in
a dose-dependent manner. While no associations be-
tween biomarker changes and best overall response were
observed, it will be of particular interest to further inves-
tigate changes in the ratio of CD137+ NK cells to NK
cells after DS-8895a treatment to understand if an in-
creased ratio may correlate with a positive treatment re-
sponse or if the addition of agonistic anti-CD137
monoclonal antibodies may enhance the treatment re-
sponse in patients with increased CD137 expression on
NK cells.
Fig. 1 Best (minimum) percent change from baseline in sum of diameters (%) of target lesions. Baseline is defined as the last measurement prior
to administration of the first dose of DS-8895a. Each vertical bar represents the best (minimum) percent change from baseline for an
individual patient
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Fig. 2 Changes in CD16-positive natural killer (NK) cells. Time-course of circulating CD16-positive NK cells (CD3−CD56+CD16+) after DS-8895a
treatment in a) Cycle 1 of Step 1 and b) Cycle 1 of Step 2, and c) the ratio of CD3−CD56+CD137+ cells to CD3−CD56+CD16+ cells in Cycle 1 of
Step 2
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Additional files
Additional file 1: Schematic of the cytotoxic effect of DS-8895a.
Abbreviations: EPHA2, erythropoietin-producing hepatocellular receptor A2;
FcγRIIIa, Fragment crystallizable gamma receptor IIIa; NK, natural killer. (TIF
785 kb)
Additional file 2: Selection criteria: sufficient organ function (DOCX 13 kb)
Additional file 3: Description of treatment-free period (DOCX 14 kb)
Additional file 4: Overall study design. Abbreviations: PK,
pharmacokinetics; Q2W, every 2 weeks. (TIF 542 kb)
Additional file 5: Definition of dose-limiting toxicities (DOCX 15 kb)
Additional file 6: Schedule of blood/serum collection (DOCX 16 kb)
Additional file 7: Disposition of patients. †One patient was excluded
from the efficacy analysis set because no efficacy data were available.
‡One patient was excluded from the PK analysis set because no PK data
were available. Abbreviation: PK, pharmacokinetics. (TIF 224 kb)
Abbreviations
ADCC: Antibody-dependent cellular cytotoxicity; AE: Adverse event;
AUC: Area under the concentration-time curve; CI: Confidence interval;
Cmax: Maximum serum concentration; DLT: Dose-limiting toxicity;
ECG: Electrocardiogram; EGFR: Epidermal growth factor receptor;
EPHA2: Erythropoietin-producing hepatocellular receptor A2; EPHRIN-
A1: EPH-related receptor tyrosine kinase ligand A1; FcγRIIIa: Fragment
crystallizable gamma receptor IIIa; HER2: Human epidermal growth factor
receptor 2; HLA: Human leukocyte antigen; IFN: Interferon; IL: Interleukin;
IRR: Infusion-related reaction; KIR: Killer cell immunoglobin-like receptor;
MCP: Monocyte chemotactic protein; MIP: Macrophage inflammatory protein;
MTD: Maximum tolerated dose; NK: Natural killer; PD-L1: Programmed death
ligand-1; PFS: Progression-free survival; PK: Pharmacokinetics; PR: Partial
response; SAE: Serious adverse event; SD: Stable disease; T1/2: Terminal
elimination half-life; Tmax: Time to reach maximum serum concentration;
TNF: Tumor necrosis factor
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